Is Rhythm Pharmaceuticals, Inc. (RYTM) a Buy, Sell, or Hold?
NASDAQ : RYTM
Rhythm Pharmaceuticals, Inc.
$106.13 USD
$4.03 (3.95%)
- Volume
- 678.25K
- Average Volume
- 795.82K
- Market Capitalization
- $7.28B
- P/E Ratio
- -33.91
- Dividend Yield
- 0.00%
- Price Target
- $142.00
- Year High
- $122.20
- Year Low
- $74.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.17
Company Overview
NASDAQ
David Meeker
Biotechnology
Healthcare
RYTM
414
US
USD
Liquidity Metrics
1.85
4.17
3.89
0.60
0.00
Sales & Valuation
$189.76M
33.52
58.70
-60.43
-1.77
Profitability
-$3.11
-$196.54M
-93.33%
-92.89%
-203.25%
-45.82%
P/E Metrics
-33.91
2.78
2.78
Analyst Price Target & Rating
$142.00
$155.00
$125.00
1/5
21 Analysts
-25.26%
Financial Health Scores
8.72
3/9
$326.89M
$442.32M
$319.41M
-$181.96M
Key Metrics (TTM)
$7.17B
33.01
-39.66
4.17
-203.25%
-56.40%
-2.92%
-1.72%
317 days
Company Executives
| Name | Title |
|---|---|
| Jim Flaherty | Senior Vice President & General Counsel |
| Hunter C. Smith | Chief Financial Officer & Treasurer |
| Joseph Shulman | Chief Technical Officer |
| Yann Mazabraud | Executive Vice President & Head of International |
| Sarah Ryan | Vice President of Sales & Marketing |
| Christopher German | Corporate Controller & Principal Accounting Officer |
| Jennifer Lee | Executive Vice President & Head of North America |
| Alastair Garfield | Chief Scientific Officer |
| David Meeker | Chairman, President & Chief Executive Officer |
| David Connolly | Head of Investor Relations & Corporate Communications |
Poll Results
No votes yet today — be the first to share your view!
About Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, includi ... ng obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
2026-07-27 07:46:37
Wall Street analysts are reshuffling their bets ahead of the busiest earnings week of the quarter, and the moves span everything from legacy automakers to crypto miners to space launch companies. Find out which names just got upgraded, downgraded, or picked up for the first time.
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
2026-07-21 17:10:00
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-21 08:00:00
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update.
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
2026-07-16 21:16:56
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
2026-07-16 21:16:00
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
2026-07-08 17:07:00
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM).
2026-06-17 12:02:18
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
2026-06-16 11:50:37
Rhythm Pharmaceuticals, Inc. (NASDAQ: RGPX) reported that setmelanotide therapy produced robust, sustained and clinically significant weight loss in patients with acquired hypothalamic obesity at 2.5 years. Alongside the long-term setmelanotide results, Rhythm reported that bivamelagon therapy achieved progressive reductions in body mass index and hunger measures in patients with acquired hypothalamic obesity at one year.
Frequently Asked Questions
-
What is the current Rhythm Pharmaceuticals, Inc. (RYTM) stock price?
-
Rhythm Pharmaceuticals, Inc.(NASDAQ:RYTM) stock price is $106.13 in the last trading session. During the trading session, RYTM stock reached the peak price of $122.2 while $74.5 was the lowest point it dropped to. The percentage change in RYTM stock occurred in the recent session was 3.95% while the dollar amount for the price change in RYTM stock was $4.03.
-
RYTM's industry and sector of operation?
-
The NASDAQ listed RYTM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RYTM?
-
Jim Flaherty | Senior Vice President & General Counsel
Hunter C. Smith | Chief Financial Officer & Treasurer
Joseph Shulman | Chief Technical Officer
Yann Mazabraud | Executive Vice President & Head of International
Sarah Ryan | Vice President of Sales & Marketing -
How many employees does RYTM have?
-
Number of RYTM employees currently stands at 414. RYTM operates from 222 Berkeley Street, Boston, MA 02116, US.
-
Link for RYTM official website?
-
Official Website of RYTM is: https://www.rhythmtx.com
-
How do I contact RYTM?
-
RYTM could be contacted at phone #857 264 4280 and can also be accessed through its website. RYTM operates from 222 Berkeley Street, Boston, MA 02116, US.
-
How many shares of RYTM are traded daily?
-
The average number of RYTM shares traded daily for last 3 months was 795.82K.
-
What is the market cap of RYTM currently?
-
The market value of RYTM currently stands at $7.28B with its latest stock price at $106.13